Drug
Aripiprazole
Aripiprazole: highest development phase Post-Market, developed by Bristol-Myers Squibb, Otsuka. 11 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Bristol-Myers Squibb, Otsuka
Trials
| Drug | Phase | Indication |
|---|---|---|
| Aripiprazole NCT01227668 | Post-Market | Irritability Associated With Autistic Disorder |
| Aripiprazole NCT00220636 | Post-Market | Depressive Disorder, Major |
| Aripiprazole (Fixed dose) NCT00876343 | Phase 3 | Major Depressive Disorder |
| Aripiprazole NCT00292409 | Phase 3 | Schizophrenia and Schizoaffective Disorder |
| Aripiprazole NCT02435836 | Phase 3 | Schizophrenia |
| Aripiprazole NCT01418339 | Phase 3 | Tourette's Disorder |
| aripiprazole NCT00041678 | Phase 3 | Alzheimer Disease |
| Aripiprazole NCT01942148 | Phase 3 | Schizophrenia |
| Aripiprazole (BMS-337039) NCT01438060 | Phase 3 | Dementia, Alzheimer Type |
| Aripiprazole Oral Solution NCT03487783 | Phase 3 | Tourette Syndrome |
| Aripiprazole NCT00102479 | Phase 1 | Schizophrenia |
Latest
No recent events.
Follow Aripiprazole on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.